Hologic, Inc. (NASDAQ:HOLX) Shares Sold by SVB Wealth LLC

SVB Wealth LLC reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 17.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,204 shares of the medical equipment provider’s stock after selling 4,090 shares during the period. SVB Wealth LLC’s holdings in Hologic were worth $1,372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in HOLX. Macquarie Group Ltd. increased its position in Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after buying an additional 4,363,687 shares in the last quarter. Norges Bank acquired a new position in Hologic during the 4th quarter valued at about $175,900,000. Arrowstreet Capital Limited Partnership increased its position in Hologic by 110.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock valued at $145,664,000 after buying an additional 995,854 shares in the last quarter. Qube Research & Technologies Ltd increased its position in Hologic by 117.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock valued at $95,651,000 after buying an additional 743,557 shares in the last quarter. Finally, Prudential Financial Inc. increased its position in Hologic by 246.0% during the 1st quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock valued at $70,730,000 after buying an additional 654,628 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Up 0.2 %

Shares of HOLX stock opened at $75.10 on Friday. The stock has a 50 day moving average of $75.71 and a 200 day moving average of $72.50. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The stock has a market cap of $17.63 billion, a P/E ratio of 35.59, a P/E/G ratio of 2.54 and a beta of 1.00. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $87.88.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. Hologic’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period last year, the business earned $1.07 earnings per share. As a group, sell-side analysts expect that Hologic, Inc. will post 4.01 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on HOLX shares. UBS Group increased their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Evercore ISI raised their price objective on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Wednesday, April 10th. Finally, Raymond James raised their price objective on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Hologic presently has an average rating of “Hold” and a consensus price target of $87.00.

Insider Activity

In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock worth $2,473,443 over the last three months. 1.75% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.